1. Competitor Dynamics Overview
Over the past quarter the PEEK value chain shows a clear pattern: “global majors retrench, domestic players scale up.” Celanese is relocating capacity, Victrex defends the high end, while Zhongyan, Xinhan, and Zhongxin accelerate integration and capacity expansion, pushing localization toward the 60% target.
2. Key Developments
| Company | Key Move | Impact |
|---|---|---|
| Celanese | Jun 4: close S. Korea plant, shift output to China/India | Supply-chain reset; possible Asia delivery volatility |
| Victrex | Launched PFAS-free FG™700 food-grade PEEK; showcased thermoplastic composites at JEC 2026 | Defends medical/food premium barrier |
| Zhongyan (688716) | May 14: ~RMB1.2bn for 10kt PEEK + 2kt fluoroketone integrated plant | Post-completion capacity ~11kt, jumps from 4th to leader |
| Xinhan (301076) | DFBP 4kt now; +2.4kt phase II this year to 12.2kt; RMB1bn placement; extends into downstream PEEK | Set to become world’s #1 DFBP supplier |
| Zhongxin Fluor | 5kt DFBP trial production; cost ~40% below import | Strengthens upstream leverage, tied to Victrex |
| Wote | ~1kt PEEK line under construction; BYD robot-component order | Second-tier taking shape |
3. Competitive Landscape
- Price: domestic standard PEEK at RMB 300k–500k/t (import 800–1,000 RMB/kg); medical grade RMB 800k–1,000k/t — roughly 1/3 cost edge.
- Demand: humanoid robots (Tesla Optimus 5–7kg/unit), medical-device green channel, and semiconductor CMP rings are core growth drivers.
- Structure: localization in golden window; 2026 localization target 60%.
4. Recommendations
- Lock upstream: sign long-term deals with Zhongyan/Xinhan to hedge DFBP price risk from Victrex hikes.
- Target robotics/medical: prioritize robot-joint and implant-grade grades; build certification barriers (FDA/ISO).
- Differentiate: avoid Victrex-dominated pure resin; focus on CF/GF reinforced and custom parts for higher margin.
- Exploit Celanese transition window: capture auto/electronics clients during its Asia delivery volatility.
Leave a Reply